Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 5, 2015

View Archived Issues

ATRX gene mutations identified as a potential biomarker for clinically aggressive PCC/PGL

Ono Pharmaceutical updates progress of third quarter of fiscal 2014

Shionogi reports milestones of third quarter of fiscal 2014

Isis Pharmaceuticals reports data from phase II study of ISIS-PTP1B Rx in type 2 diabetes

Belsomra now available in the U.S. to treat insomnia

InMed begins program targeting Epidermolysis bullosa simplex

ACEA Biosciences patents BTK inhibitors

CytoDyn concludes phase II PRO-140 trial and submits phase III protocol to FDA

Leading BioSciences cleared to begin phase II study of LB-1148 in septic shock

Regulus earns milestone payment under Biogen Idec research collaboration

Launch of new biotech start-up OptiKira

Diamyd Medical starts pilot trial of type 1 diabetes vaccine injected into lymph nodes

BioLight updates development progress of tests for bladder cancer and dry eye

Wound care specialist AlliquaBioMedical agrees to acquire device developer Celleration

NIHR and Janssen to study rheumatoid arthritis response to anti-TNF therapy

Polaris initiates phase I trial of ADI-PEG20 plus FOLFOX in gastrointestinal cancers

U.S. researchers prepare new deuterated droxidopa derivatives

Amgen releases topline results from phase III study of adalimumab biosimilar ABP-501

Scientists at BMS disclose XIAP inhibitors

New AXL kinase inhibitors patented by Ono Pharmaceuticals

Cynata's mesenchymal stem cells to be tested in animal model of lung fibrosis

Obinutuzumab extends PFS in phase III indolent non-Hodgkin's lymphoma trial

FDA accepts for review CSL Behring's BLA for rIX-FP

New data presented for an inhibitor of tau aggregation in Alzheimer's disease treatment

rEVO Biologics funds pre-eclampsia research center at Yale University

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...